In this review, we have investigated pre-clinical studies that described the safety, efficacy, and adverse effects of anti-PD-1/PD-L1 antibodies in gynecologic cancers and the ongoing clinical trials with these agents. The gene discussed is CD274; the disease is female reproductive organ cancer.